Juva Life Announces Filing of Patent on JUVA-041 – Small Molecule Isolated from the Cannabis Plant
Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) has filed a patent application with the USPTO for JUVA-041, a non-cannabinoid molecule aimed at treating inflammation. This follows the previous patent filing for JUVA-019, highlighting the company's commitment to developing safe, effective anti-inflammatory drugs. CEO Doug Chloupek emphasized that these compounds avoid regulatory issues associated with THC, marking a key development in the company's pharmaceutical strategy. Juva aims to partner with leading firms for further product development.
- Successful patent application for JUVA-041, strengthening intellectual property portfolio.
- JUVA-041 and JUVA-019 identified as promising drug candidates for chronic inflammation.
- Compounds offer a regulatory advantage by being non-cannabinoid.
- None.
Potent Anti-Inflammatory Non-Cannabinoid Molecule
VANCOUVER, British Columbia, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRANKFURT: 4VV) (“Juva Life,” “Juva” or the “Company”), a life science company with pharmaceutical research and development and consumer-facing operations in cannabis production and distribution, announced today the filing of patent application with the United States Patent and Trademark Office (USPTO) on JUVA-041, a small molecule isolated from the cannabis plant that has been identified by Juva’s in-house research team.
The news follows the Company’s identification of non-cannabinoid compound JUVA-019, on which the Company has filed a patent application and has conducted preclinical research showing that the compound is effective as a stand-alone compound in inhibiting inflammation by modulating certain biomarkers in the body. Through its research division, Juva scientists have continuously been evaluating an internally curated database of compounds found in the cannabis plant for their therapeutic benefit, leading to the identification of the two proprietary compounds: JUVA-019 and JUVA-041, which the Company has nominated as drug candidates for further pre-clinical investigation. Current efforts are focused on advancing both compounds through phenotypic models of chronic diseases of aging.
“Filing the patent application on JUVA-041 is a major milestone for Juva as we now have two drug candidates that we believe hold significant promise in addressing unmet needs for safe and effective small molecule anti-inflammatory drugs, and the Company’s IP will be protected,” said Doug Chloupek, CEO and Founder of Juva. “These molecules are not cannabinoids and as such they do not possess regulatory encumbrances associated with THC class.”
The filing of a patent application on JUVA-041, along with the Company’s patent application on JUVA-019, signify the next step along the path of pharmaceutical development for these compounds, two non-cannabinoid molecules that have been clinically observed to hold significant potential to inhibit inflammation.
The Company’s business strategy is to leverage its unique knowledge of the chemistry and anti-inflammatory mode of action of non-cannabinoid compositions contained within cannabis to develop safe and effective therapeutics. The Company intends to develop products through preclinical in vivo validation studies, and partner with leading pharmaceutical and consumer companies seeking anti-inflammatory bioactives for their product pipelines. Previously on October 6, 2021, the Company filed a provisional patent with the USPTO on the method of use of the natural compositions, and composition of matter claims on non-naturally occurring semi-synthetic and synthetic analogs.
ON BEHALF OF THE BOARD,
-Doug Chloupek-
Doug Chloupek, CEO and Founder
Juva Life Inc.
About Juva Life Inc. (CSE: JUVA) (OTCQB: JUVAF) (FRA: 4VV)
Juva Life is employing state-of-the-art science to discover, develop and commercialize safe and effective wellness and pharmaceutical products, in both the cannabis consumer segment as well as the non-cannabinoid based medical industry. The Company is successfully executing against its 2018 roadmap, initially starting with standardization of cultivation, extraction, and formulation to offer consumers reproducible benefits. Juva is building upon these natural product process chemistry skills, to now include discovery pharmacology. The Company will leverage revenue derived from its retail operations to advance its consumer and clinical development efforts of Juva-019 and Juva-041, as well as other potentially valuable non-cannabinoid bioactives with significant consumer and pharma products applications. Juva is working to bring the Cannabis market face to face with the sector’s next generation investment grade business model. Find out more at: https://juvalife.com/.
For further information, please contact:
Juva Life Investor Relations
Tel: +1 833-333-5882 (JUVA)
Email: inquiries@juvalife.com
Forward Looking Statement
This news release contains statements and information that, to the extent that they are not historical fact, may constitute “forward-looking information” within the meaning of applicable securities legislation. Forward-looking information may include financial and other projections, as well as statements regarding future plans, objectives, or economic performance, or the assumption underlying any of the foregoing. In some cases, forward-looking statements can be identified by terms such as “may”, “would”, “could”, “will”, “likely”, “except”, “anticipate”, “believe”, “intend”, “plan”, “forecast”, “project”, “estimate”, “outlook”, or the negative thereof or other similar expressions concerning matters that are not historical facts. Examples of such statements include, but are not limited to, statements with respect to the objectives and business plans of the Company; product development, commercialization strategy and future collaborations.
Forward-looking information involves known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, including, without limitation, risks relating to the future business plans of the Company; risks that the Company will not be able to retain its key personnel; risks that the Company will not be able to secure financing on reasonable terms or at all, as well as all of the other risks as described in the Company’s management discussion and analysis for year ended December 31, 2020 under the heading “Risks and Uncertainties”. Accordingly, readers should not place undue reliance on any such forward-looking information. Further, any forward-looking information speaks only as of the date on which such statement is made. New factors emerge from time to time, and it is not possible for the Company’s management to predict all of such factors and to assess in advance the impact of each such factor on the Company’s business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking information. The Company does not undertake any obligation to update any forward-looking information to reflect information or events after the date on which it is made or to reflect the occurrence of unanticipated events, except as required by law, including securities laws.
The CSE does not accept responsibility for the adequacy or accuracy of this release.
FAQ
What is JUVA-041 and why is it important for Juva Life Inc.?
What other compounds has Juva Life Inc. patented recently?
What does the patent filing for JUVA-041 signify for Juva Life Inc.?
How does JUVA-041 differ from cannabinoid drugs?
What is the strategic plan for Juva Life Inc. regarding JUVA-041?
